Business · Companies · 1 day ago
Bayer raises 2026 profit outlook as pharmaceuticals outperform
German company Bayer raised its profit outlook for 2026 after its pharmaceutical business performed better than expected.
The company said stronger medicines performance helped offset pressure in its agricultural and consumer-health divisions.
Bayer’s pharmaceutical sales reached 4.68 billion euros in the third quarter, 5% above analysts’ expectations.
Its adjusted operating profit was also about 13% higher than analysts expected.
The agricultural division fell short of expectations, with adjusted operating profit of 101 million euros against an expected 164 million euros.
Bayer has faced heavy debt and costly Roundup lawsuits since it bought Monsanto for $63 billion in 2018.
The company also lowered its year-end net debt forecast by 1 billion euros, to between 28 billion and 29 billion euros.
Bayer raised its 2026 profit forecast after its pharmaceutical business performed better than expected.
The company now expects adjusted operating profit of €9.8 billion to €10.3 billion, up from its previous range of €9.6 billion to €10.1 billion.
Pharmaceutical sales reached €4.68 billion in the third quarter, 5% above analysts’ expectations.
Bayer also lowered its forecast for net financial debt by €1 billion, to between €28 billion and €29 billion.
Its agricultural science division’s adjusted operating profit was €101 million, below analysts’ expectations of €164 million.
- Who
- Bayer, the German pharmaceutical and agricultural group.
- What
- It raised its 2026 profit forecast after stronger-than-expected pharmaceutical performance.
- When
- Tuesday, November 3, 2026.
- Where
- Germany; Bayer shares were trading in Frankfurt and European markets.
- Why
- Its pharmaceutical business performed better than expected and helped offset pressures in other divisions.
This story does not have two clearly opposing sides.
Bayer acquired Monsanto for $63 billion.
Bayer’s pharmaceutical division recorded sales of €4.68 billion.
Bayer raised its 2026 adjusted operating profit forecast to €9.8 billion to €10.3 billion.
- 2026 adjusted operating profit forecast
- €9.8 billion–€10.3 billion, up from €9.6 billion–€10.1 billion
- Pharmaceutical sales, third quarter
- €4.68 billion
- Pharmaceutical sales versus analysts’ expectations
- 5% higher
- Net financial debt forecast
- €28 billion–€29 billion, reduced by €1 billion
- Agricultural science adjusted operating profit
- €101 million, versus analysts’ expectations of €164 million
5 sources
Bayer Raises Profit Outlook on Strong Demand for Drugs
Bayer corre a Francoforte dopo la trimestrale e il rialzo stime 2026
Bayer eleva previsão de lucro para 2026 com unidade farmacêutica superando previsões
Bayer Shares Jump After Pharma Recovery Prompts Outlook Raise
Bayer verhoogt winstverwachting voor 2026
What people are saying
We have reached an inflection point in the growth trajectory of the pharmaceutical division and are beginning to see the other side.